Skip to content

Organon – Denmark logo

Main menu
    • Vores historie
    • Vores fokus
    • Vision, mission & values
    • Miljø og samfundsansvar
    • Medier
    • Pressemeddelelser
  • Kom med i vores team

Kontakt os

Visit Organon's LinkedIn Opens a new window

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Here for her health

Det vi tror på

Vi tror på en bedre og sundere hverdag for alle kvinder. Vi mener, at fokus på kvinders sundhed er afgørende for en sundere verden. Vi er en ny virksomhed og vi vil starte med, at lytte til hvilke sundhedsbehov kvinder faktisk har. På denne måde kan vi udvikle behandlinger skræddersyet til kvinder. Det gør vi, fordi vi ved, at der kan gøres så meget mere for kvinders sundhed.

Lær os at kende

 

Vores fokusområder

Vi har allerede en solid portefølje med over 60 godkendte lægemidler og andre produkter

Lær mere om vores fokusområder
Kvinders sundhed

Vi ved, at kvinder har brug for flere valgmuligheder, når det gælder deres egen sundhed. Gennem vores portefølje af produkter, der er specielt designet til kvinders behov, er det vores mål, at skabe en bedre og sundere hverdag for alle kvinder.

Biosimilære lægemidler

Ved at lette adgangen til biosimilære lægemidler, giver vi samtidig flere patienter flere muligheder for behandling

Etablerede lægemidler

Vi har en række af etablerede lægemidler, som bruges til behandling inden for vigtige områder som hjerte-karsygdom, lunge- og hudsygdomme samt non-opioid smertelindring.

Previous
Next

Karriere

Sammen finder vi løsninger, som virkelig betyder noget for kvinders sundhed

Vores medarbejdere er en del af en verdensomspændende organisation af
flere tusinde mennesker. Vi har et fælles ønske om, at forbedre kvinders sundhed både inden for vores egen virksomhed og i resten af verden.

Bliv en af os

Ledelse

Få mere at vide om vores ledelse

Få mere at vide

Medier

Hold dig opdateret

Hold dig opdateret om alt, der vedrører Organon, ved at se vores seneste nyheder.

Læs vores seneste nyheder

Følg os på sociale medier

Linkedin icon Opens a new window
Organon – Denmark logo

Virksomhed

  • Om os
  • Vision, mission & values

Ressourcer

  • Medier

Kontakt os

  • Kontakt os
  • Cookie-politik
  • Fortrolighedspolitik
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept